U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07152782) titled 'T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis' on Aug. 26.
Brief Summary: A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer With Brain Metastasis
HER2-positive Breast Cancer
Intervention:
DRUG: Neratinib
Neratinib, as an irreversible pan-HER tyrosine kinase inhibitor (TKI), holds a unique position in the treatment of HER2-positive breast cancer. F...